Compare · ISO vs MDT
ISO vs MDT
Side-by-side comparison of IsoPlexis Corporation (ISO) and Medtronic plc. (MDT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ISO and MDT operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- MDT is the larger of the two at $94.69B, about 397.2x ISO ($238.4M).
- MDT has hit the wire 13 times in the past 4 weeks while ISO has been quiet.
- MDT has more recent analyst coverage (25 ratings vs 7 for ISO).
- Company
- IsoPlexis Corporation
- Medtronic plc.
- Price
- $0.75+2.09%
- $73.72-0.34%
- Market cap
- $238.4M
- $94.69B
- 1M return
- -
- -7.84%
- 1Y return
- -
- -13.86%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 0
- 13
- Recent ratings
- 7
- 25
IsoPlexis Corporation
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States and Europe. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations without the need for highly specialized informatics professionals, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
Medtronic plc.
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Latest ISO
- SEC Form SC 13D/A filed by IsoPlexis Corporation (Amendment)
- SEC Form 15-12G filed by IsoPlexis Corporation
- IsoPlexis Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Leadership Update, Financial Statements and Exhibits
- SEC Form S-8 POS filed by IsoPlexis Corporation
- SEC Form S-8 POS filed by IsoPlexis Corporation
- SEC Form 4 filed by Khakhar Rajesh T.
- SEC Form 4 filed by Myers Jason W.
- SEC Form 4 filed by Ho Gregory P.
- SEC Form 4 filed by Heath James R
- SEC Form 4 filed by Zhou Jing
Latest MDT
- morph Launches the World's First Shapeshifting Soft Robotics Cells Platform to Bring Physical AI into Real-World Applications
- SVP, Chief HR Officer Walter Matthew R. converted options into 9,149 units of Ordinary Shares, increasing direct ownership by 28% to 41,529 units (SEC Form 4)
- EVP & Pres Neuroscience Wall Brett A. converted options into 26,907 units of Ordinary Shares, increasing direct ownership by 49% to 82,183 units (SEC Form 4)
- Chairman and CEO Martha Geoffrey converted options into 94,963 units of Ordinary Shares, increasing direct ownership by 38% to 343,099 units (SEC Form 4)
- EVP, Pres MedSurg and Americas Marinaro Michael converted options into 18,994 units of Ordinary Shares, increasing direct ownership by 37% to 70,593 units (SEC Form 4)
- EVP & President Cardiovascular Kiil Harry Skip converted options into 15,195 units of Ordinary Shares, increasing direct ownership by 46% to 48,233 units (SEC Form 4)
- Chief Accounting Officer Blomquist Denise L. converted options into 1,712 units of Ordinary Shares, increasing direct ownership by 13% to 14,974 units (SEC Form 4)
- SEC Form SD filed by Medtronic plc.
- Goldman resumed coverage on Medtronic with a new price target
- Medtronic announces intent to acquire SPR Therapeutics, Inc., expanding care options for people living with chronic pain